An exatecan derivative based linker-payload platform leads to ADC products with promising anti-tumor efficacy and potential low interstitial lung disease (ILD) risk

被引：0
|
作者：
Lin, S. [1 ]
Shi, R. [2 ]
Li, B. [1 ]
Qiu, Y. [2 ]
Hua, H. [1 ]
Zhang, Y. [1 ]
机构：
[1] Dual Biol, Res & Dev, Shanghai, Peoples R China
[2] Dual Biol, Res & Dev, Princeton, NJ USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
251
引用
收藏
页码：S91 / S91
页数：1
相关论文
共 2 条
  • [1] The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients-The Putative Mechanism Behind ILD
    Sloot, Willem N.
    Bertotti, Elisa
    Onidi, Manuela
    Paoletti, Andrea
    De Salve, Ilse
    Tavano, Patrizia
    Vigna, Enrico
    Mueller, Gundi
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2025,
  • [2] Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses
    Attinger-Toller, Isabella
    Probst, Philipp
    Bertrand, Romain
    Renard, Emma
    Stark, Ramona
    Santimaria, Roger
    Grabulovski, Dragan
    Schlereth, Bernd
    Spycher, Philipp Rene
    CANCER RESEARCH, 2023, 83 (08)
1